Lucid Diagnostics Inc.
No SEC Form 4 filings for $LUCD in the last 30 days.
See all $LUCD insider activity →Needham reiterated a Buy rating on Lucid Diagnostics Inc (NASDAQ:LUCD) and set a $3.00 price target, versus about $0.97. The article cites Q2 2026 EsoGuard test volume up 1% to 2,770, revenue of $1.47M vs $1.43M consensus, and a 6-cent-per-share loss. It notes about $33M cash and continued negative free cash flow.
Lucid Diagnostics (NASDAQ: LUCD) reported Q2 2026 revenue of $1.5 million, up 17% QoQ, driven by 2,770 EsoGuard tests. The company said Concert issued its first Laboratory Benefit Manager coverage policy for EsoGuard. Cash was $33.4 million at June 30, with $11.3 million quarterly burn. It awaits a Medicare draft LCD and is progressing with VA.
Lucid Diagnostics (NASDAQ:LUCD) reported Q2 2026 revenue of $1.5 million, up 17% QoQ, with 2,770 EsoGuard tests in the quarter. The company said it secured its first lab benefit manager coverage policy from Concert and is awaiting Medicare draft LCD publication. It reported $33.4 million cash, $11.3 million quarterly burn, and $16.8 million net proceeds from a stock offering.
Over the past 7 days, alphai's AI scored 9 news stories mentioning LUCD (Lucid Diagnostics Inc.). Coverage has skewed bullish: 6 bullish, 2 neutral, and 1 bearish.
Recent LUCD coverage spans earnings, financial news and market movers.
Analyst target reiteration plus coverage timing thesis may support near-term sentiment, but the article also highlights ongoing cash burn and losses.
The first LBM coverage policy is a concrete reimbursement-access milestone that should improve future cash collection and revenue recognition mix.
The Concert LBM coverage milestone and Medicare LCD wait are the key near-term drivers for EsoGuard market access expectations.
Near-term trading focus is likely on Medicare local coverage timing and reimbursement conversion, not the modest revenue beat.
The earnings miss and weak revenue print increase near-term downside risk until management commentary clarifies trajectory and estimate revisions.
alphai scores every news story that mentions LUCD with an AI model for sentiment and relevance, and aggregates insider trades from Lucid Diagnostics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Needham reiterated a Buy rating on Lucid Diagnostics Inc (NASDAQ:LUCD) and set a $3.00 price target, versus about $0.97. The article cites Q2 2026 EsoGuard test volume up 1% to 2,770, revenue of $1.47M vs $1.43M consensus, and a 6-cent-per-share loss. It notes about $33M cash and continued negative free cash flow.
4 min readLucid Diagnostics (NASDAQ: LUCD) reported Q2 2026 revenue of $1.5 million, up 17% QoQ, driven by 2,770 EsoGuard tests. The company said Concert issued its first Laboratory Benefit Manager coverage policy for EsoGuard. Cash was $33.4 million at June 30, with $11.3 million quarterly burn. It awaits a Medicare draft LCD and is progressing with VA.
6 min readLucid Diagnostics (NASDAQ:LUCD) reported Q2 2026 revenue of $1.5 million, up 17% QoQ, with 2,770 EsoGuard tests in the quarter. The company said it secured its first lab benefit manager coverage policy from Concert and is awaiting Medicare draft LCD publication. It reported $33.4 million cash, $11.3 million quarterly burn, and $16.8 million net proceeds from a stock offering.
6 min readLucid Diagnostics reported Q2 2026 revenue of $1.47 million, up 17% sequentially and above the $1.43 million estimate, driven by more EsoGuard insurance claims recognized. EPS was a loss of 6 cents, matching forecasts. The company performed 2,770 EsoGuard tests and reiterated Medicare coverage as the key near-term catalyst; shares fell slightly in premarket.
5 min readLucid Diagnostics Inc. (LUCD) reported Q2 adjusted EPS loss of $0.06 per share, wider than the Zacks Consensus Estimate of a $0.04 loss. Revenue was $1.47M for the quarter ended June 2026, missing consensus by 1.73% and up from $1.16M a year earlier. The article cites a Zacks Rank #3 (Hold) and upcoming consensus EPS of -$0.04 on $2M revenue for the next quarter.
3 min readLucid Diagnostics (NASDAQ: LUCD) reported Q2 EPS of -$0.0600, matching the analyst estimate, and revenue of $1.47M, above the $1.43M consensus. The stock closed at $0.98. The article notes recent EPS revisions and a “weak performance” financial health score from InvestingPro.
3 min readLucid Diagnostics Inc. (LUCD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy
6 min readLucid Diagnostics Inc. (Nasdaq: LUCD) reported 2Q26 results for the quarter ended June 30, 2026. EsoGuard-related revenue was $1.5 million and 2,770 EsoGuard tests were processed. The company secured a commercial coverage policy via Concert and said it had $33.4 million cash. GAAP net loss was about $14.7 million. A call is scheduled Aug. 13.
3 min readLucid Diagnostics said Concert issued a positive coverage policy for its EsoGuard Esophageal DNA Test. The policy, effective July 2026, deems the test medically necessary for patients meeting American College of Gastroenterology screening criteria, based on guidelines and peer-reviewed evidence. Lucid said Concert was acquired by Lyric and that multiple Concert client health plans have adopted the policy.
3 min readLucid Diagnostics (Nasdaq: LUCD) said Concert issued a positive commercial coverage policy effective July 2026 for its EsoGuard esophageal DNA test, citing guideline and peer-reviewed evidence and deeming the test medically necessary for patients meeting ACG screening criteria. Lucid said multiple Concert client health plans have adopted the policy.
3 min read
